Nintedanib Zentiva (Nintedanib Esylate)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, PDGFR and FGFR—thereby inhibiting fibroblast proliferation, migration and extracellular matrix formation, while also reducing angiogenesis. This dual action underlies its antifibrotic and anticancer effects.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and other individual factors. No standardized regimen is provided here.

Safety data for Nintedanib during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It is generally avoided in pregnant or nursing women unless the potential benefit outweighs the risk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for fibrotic lung disease is pirfenidone, which has a different mechanism—modulating cytokine production and oxidative stress. Nintedanib’s broader kinase inhibition offers anti‑angiogenic activity and is also approved for certain lung cancers, whereas pirfenidone is limited to idiopathic pulmonary fibrosis.

Nintedanib Zentiva should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and excessive heat. Keep the container tightly closed and out of direct sunlight.

The medication is taken orally, usually as whole tablets swallowed with a glass of water. It is generally recommended to be taken with food to lessen gastrointestinal discomfort, but patients should follow the specific instructions given by their healthcare provider.

Serious adverse events include hepatotoxicity (significant liver enzyme elevations or liver injury), bleeding complications (especially when combined with anticoagulants), and cardiovascular events such as myocardial infarction or stroke. Prompt medical evaluation is advised if any of these occur.

Patients with severe hepatic impairment, uncontrolled bleeding disorders, or those taking strong CYP3A4 inhibitors should avoid Nintedanib. Additionally, individuals who are pregnant, planning pregnancy, or breastfeeding should not use it unless a clinician determines the benefits outweigh the risks.